Amsterdam: The European Union (EU) gave official approval Monday for the coronavirus vaccine developed by BioNTech and Pfizer. The coronavirus vaccine will be used across the 27-nation bloc. This means that the countries can begin administering the first shots to their citizens shortly after Christmas.
The EUs executive commission gave the green light just hours after the European Medicines Agency (EMA) said the vaccine meets safety and quality standards. Brussels had been expected to take two or three days to endorse the market authorization move.
“As we have promised, this vaccine will be available for all EU countries at the same time, on the same conditions,” said European Commission (EC) president Ursula von der Leyen. “This is a very good way to end this difficult year, and to finally start turning the page on COVID-19,” she added.
Deliveries of the vaccine had been penciled in to start this coming Saturday, with inoculations beginning across the EU anytime from December 27 to 29.
The same vaccine was authorised in Britain and the United States weeks ago. It prompted pressure from EU governments for EMA to speed up its approval process as virus cases surged again across the continent.
EMA originally set December 29 as the date for evaluating the vaccine. However, it moved up the meeting to Monday after calls from the German government and others for the agency to move more quickly.
Harald Enzmann, the head of EMAs expert committee, dismissed any suggestion that political influence had affected the decision.
“The focus was exclusively on the science,” Enzmann told reporters. “that was a scientific assessment, full stop.”
The Amsterdam-based EMA is responsible for approving all new drugs and vaccines across the 27 EU member states, Iceland, Liechtenstein and Norway. It is roughly equivalent to the US Food and Drug Administration.
The vaccine has already been given some form of regulatory authorisation in at least 15 countries.
Britain, Canada and the US have authorised the vaccine to be used according to emergency provisions, meaning the shot is an unlicensed product whose temporary use is justified by the pandemic that has killed almost 1.7 million people worldwide, according to a tally by Johns Hopkins University.
Switzerland became the first country Saturday to authorize the vaccine according to the normal licensing procedure. EMAs conditional market authorisation also followed the regular process, only on an accelerated schedule and under the condition that the pharmaceutical companies submit follow-up data on their vaccine for the next year.